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Balaji Venugopal1*, Jawaher Ansari1, Michael Aitchison1,2, Lye Mun Tho1,2, Roderick Campbell3 and Rob J Jones1,2Abstract
Background: Renal cell carcinoma (RCC) is a histopathologically and molecularly heterogeneous disease with the
chromophobe subtype (chRCC) accounting for approximately 5% of all cases. The median overall survival of
advanced RCC has improved significantly since the advent of tyrosine kinase inhibitors and mammalian target of
rapamycin (mTOR) inhibitors. However, high-quality evidence for the use of new generation tyrosine kinase
inhibitors in patients with advanced chRCC is lacking. Few published case reports have highlighted the use of
temsirolimus in chRCC.
Case presentation: Here, we report the case of a 36-year-old Caucasian woman with metastatic chRCC with
predominantly skeletal metastases who was refractory to sunitinib who demonstrated a durable clinical response to
temsirolimus lasting 20 months. We review the available evidence pertaining to the use of new generation
molecularly targeted agents, in particular mTOR inhibitors in chRCC and discuss their emerging role in the management
of this disease which would aid the oncologists faced with the challenge of treating this rare type of RCC.
Conclusion: Conducting randomised clinical trials in this rarer sub-group of patients would be challenging and our
case report and the evidence reviewed would guide the physicians to make informed decision regarding the
management of these patients.
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Renal cell carcinoma (RCC) accounts for 2-3% of all
malignancies and is the seventh most common malignancy
in men and the twelfth most common malignancy in
women [1]. Molecularly targeted agents inhibiting the
angiogenic and mTOR pathways have widened the
therapeutic armamentarium for RCC and have led to
a paradigm shift in the management of this disease
particularly in the metastatic setting [2]. RCC is a
heterogeneous disease characterised by distinct histological
subtypes, molecular genetic alterations, clinical behaviour
and patient outcomes, and the subtypes include clear
cell (70-80%), papillary (10-20%), chromophobe (5%),
collecting duct (1%) and unclassifiable RCC [3].
Histological appearances of chRCC typically demonstrate
aggregates of pale cells with granular to eosinophilic
cytoplasm and prominent cell membranes. Nuclear features* Correspondence: balajivenugopal@nhs.net
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distribution, and reproduction in any mediumare particularly useful in making the diagnosis, and
distinguishing chromophobe carcinoma from other forms
of renal carcinoma and oncocytoma. The nuclei in
chromophobe carcinomas are generally dark and wrinkled,
with a surrounding peri-nuclear halo of clear cytoplasm.
Ancillary studies can also be helpful particularly if
morphology is indeterminate. Staining for Hale’s colloidal
iron is often positive and immunohistochemical markers
are usually negative for cytokeratin 20 and vimentin but
positive for cytokeratin 7 [4,5].
We report a case of a patient with a diagnosis of
metastatic chromophobe renal cell carcinoma that was
refractory to treatment with sunitinib but achieved durable
clinical response lasting twenty months upon treatment
with temsirolimus.
Case presentation
A 36-year-old woman was admitted to the emergency
department with 6 months history of left sided back pain.
Subsequent computed tomography (CT) scan and magnetic
resonance imaging (MRI) revealed a complex 3 cm masstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and osteolytic lesions within the thoracic and lumbar
vertebrae. Following this, a CT guided biopsy of the
renal mass was undertaken but this failed to provide
definitive histological diagnosis. Due to bony disease
causing impending spinal cord compression at thoracic
vertebrae T12 (without neurological deficit), she received
urgent radiotherapy (20Grays in 5 fractions) to this area
which did not result in any significant improvement in her
performance status. Following this, the decision was
taken to proceed to a left laparoscopic cytoreductive
nephrectomy and histopathological examination confirmed
this to be a chRCC (Figure 1) with final staging of pT3a,
pN1, M1 (as per American Joint Committee for Staging
Cancer version 7).
Our patient presented with 4 of the six adverse
prognostic factors as defined in the pivotal trial of
Hudes et al. (haemoglobin less than lower limit of normal,
Karnofsky performance status score of 70% and disease
requiring systemic treatment within a year of presentation),
thus categorising her within the poor prognostic grouping
[6]. Following an uneventful post-operative recovery period,
in January 2010 the patient was commenced on sunitinib
at the recommended dose of 50 milligrams (mg) once
daily for four weeks followed by two weeks off treatment.
The dose was reduced to 37.5 mg once daily after cycle 1
due to persistent grade III thrombocytopaenia. After 2
cycles of sunitinib, there was clear clinical progression
with deterioration of symptoms. CT and isotope bone
scan demonstrated increase in size and number of bony
metastases and sunitinib treatment was therefore
discontinued. Sunitinib although is licenced for the use
of both clear cell and non-clear RCC, the pivotal trial
reported by Motzer and colleagues had excluded patients
with non-clear cell RCC [7].Figure 1 Histology of chromophobe renal cell carcinoma.
Hematoxylin and eosin stained slide of the of nephrectomy
specimen showing typical features of chromophobe renal cell
carcinoma at original magnification times 400.At this point, the patient required physical aids to
mobilise due to painful lytic bony metastases of the
femur. In view of the non-clear histology and the ad-
verse prognostic factor at diagnosis, in May 2010 the
decision was then taken to commence temsirolimus
at the recommended dose of 25 mg administered as
weekly intravenous infusion. Treatment response was
monitored using serial CT and isotope bone scans.
Following 8 weeks of temsirolimus, there was significant
improvement in pain control. Mobility was significantly
better and the patient was able to mobilise independently
without aid. Bone scan at baseline (Figure 2, panel A)
when compared with the bone scan after three months
of treatment with temsirolimus demonstrated reduced
isotope uptake in the metastatic lesions (Figure 2, panel B).
CT scans showed features of stable disease without
the appearance of any new lesions. Taken together
this demonstrated a favourable response to treatment.
Toxicities of temsirolimus were minimal, which included
grade I nail changes and grade I lethargy. She also
received zolendronic acid at the dose of 4 mg as 4-weekly
intravenous infusions from three months into treatment
with temsirolimus.
Following 13 months of treatment with temsirolimus the
patient developed acute onset dyspnoea on exertion. CT
scan of the thorax revealed consolidation and interstitial
changes of both left upper and right lower lobes of the
lungs. A diagnosis of temsirolimus induced pneumonitis
was made based on clinical and radiological grounds.
Temsirolimus was withheld and antibiotics and steroids
were given. Over a period of 2 weeks, the patient responded
very well to this therapy and a chest X-ray (CXR) demon-
strated significant resolution of the consolidative changes.
Temsirolimus was re-commenced but within 2 weeks
further dyspnoea re-emerged. The patient was treated with
steroids and temsirolimus was withheld again. Following
resolution of dyspnoea treatment was re-started at a
reduced dose of temsirolimus (20 mg weekly). Following aFigure 2 Sequential isotope bone scans of the patient. Isotope
bone scans demonstrating response to treatment with reduction in
size and number of skeletal metastases when compared to baseline
(left panel, A) and 3 months after treatment (right panel, B)
with temsirolimus.
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2012, radiological evidence of disease progression with
multiple, new hepatic metastases was apparent, at which
point treatment with temsirolimus was discontinued. The
patient died of progressive disease in April 2012, 26
months after diagnosis. In conclusion, we report a case of
metastatic chRCC deriving significant clinical benefit from
temsirolimus 20 months in duration, in the absence of
prior response to sunitinib.
Discussion
The prognosis of RCC varies significantly depending
on histological sub-type, with non-clear cell histology
portending a favourable prognosis compared with clear
cell RCC [5,8]. Amongst the non-clear cell variety, patients
with chRCC demonstrate significantly higher median
overall survival compared to both clear cell and papillary
RCC. Besides the histology, tumour stage, tumour grade
and performance status are also independent prognostic
markers of survival [5]. However these data were primarily
derived prior to the advent of new generation targeted
agents. Conversely, in the metastatic setting, non-clear cell
RCCs are in general characterised by resistance to systemic
therapy and poor survival [5,8]. In clinical trials of systemic
therapy in the metastatic RCC, chRCC are continually
under-represented and usually systematically excluded
and it is difficult to draw conclusions to guide management
decisions. This is particularly relevant in the era of modern
targeted therapies, where the efficacy of newer agents
such as sunitinib and temsirolimus in chRCC treatment
remains uncertain.
The exclusion of non-clear cell RCC from clinical trials
may be driven our limited and patchy understanding of
the molecular biology of RCC. Abrogation of tumour
suppressor function of the Von Hippel-Lindau (VHL)
gene is a common feature of clear cell RCC, whereas the
driving mutations behind non-clear cell RCC carcinogenesis
are less well understood [9]. This has led to most contem-
porary clinical trials in RCC excluding patients with
non-clear cell histology leading to a poor evidence base
for this disease. However, the pivotal phase III clinical
trial comparing temsirolimus versus interferon alpha
(IFN) in metastatic RCC with at least three adverse poor
prognostic features by Hudes and colleagues did include
approximately 18% (n=37) of patients with non-clear
cell RCC [6]. In this trial, there was only one patient
with chRCC but the outcome of this specific patient is
unknown [10]. In a subgroup analysis, the median overall
survival was comparable for patients with clear cell and
non-clear cell histology when treated with temsirolimus
(10.7 months versus 11.6 months), whereas patients with
clear cell and non-clear cell histology treated with IFN
had poorer median OS (8.2 months versus 4.3 months)
[10]. It appears that although temsirolimus demonstratedsignificant anti-tumour activity across all histological
subtypes, the differential gain in efficacy of temsirolimus
versus IFN seemed to be greatest in non-clear cell RCC.
With the caveats of over-interpretation of data derived
from retrospective subgroup analysis and the small
numbers of patient involved, these data suggest that
temsirolimus may have beneficial activity against non-clear
cell RCC.
Choueiri et al. reported on sunitinib and sorafenib as first
line therapy for metastatic papillary and chromophobe
RCC in a series of 53 patients gathered from 4 centres
in France and one in the USA [11]. Of the 12 patients with
metastatic chRCC, only three had a partial response
(two patients treated with sorafenib and one treated
with sunitinib). This suggests that VEGF targeted tyrosine
kinase inhibitors may only have modest activity against
chRCC. This data, however, should be interpreted with
caution in view of the small sample size.
Sporadic case reports exist in the literature documenting
disease response of chRCC to mTOR inhibitors that
have licenced for use in RCC, namely everolimus and
temsirolimus. Larkin and colleagues have reported a
case of a patient with chRCC with an ongoing 24 month
period of disease response to everolimus as a second
line treatment, following initial treatment with sunitinib
[12]. Paule et al. report a case of chRCC responding to
temsirolimus after initial treatment with interferon alpha
and sorafenib [13]. Another case report also describes
response to temsirolimus in a patient with metastatic
chRCC who had initially responded to sunitinib and
sorafenib [14]. A review of Surveillance Epidemiology
and End Result (SEER)-17 program indicated that the
deaths attributed to chRCC was between 4–9 cases per
year and this accounted for 1% of total mortality rate
due to RCC [15]. This report by Shuch and colleagues
emphasize the rarity of chRCC and the challenges
faced by clinicians in treating such rare tumours.
A prospective randomised clinical trial of first-line
sunitinib versus everolimus in patients with metastatic
non-clear cell RCC (ASPEN) is currently recruiting patients
in the United Kingdom and North America [16]. The
results of this trial are eagerly awaited, including impli-
cations for chRCC management in particular. The ideal
scenario would be if the oncology community could
perform adequately powered randomised clinical trials
for chRCC specifically; however this would be fraught
with various challenges involved in conducting clinical
trials for rarer tumour types.
Conclusion
In conclusion, there is insufficient evidence to produce
definitive treatment recommendations for metastatic
chRCC. Nevertheless there is an emerging theme that
mTOR inhibitors are important in the management of
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would indicate that temsirolimus is a reasonable first
line treatment choice in the metastatic chRCC.
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